Non-fatal MI

1.32 (1.02-1.72)

23

30

CHD death

1.18 (0.70-1.97)

6

7

Invasive breast cancer^b

1.26 (1.00-1.59)

30

38

Stroke

1.41 (1.07-1.85)

21

29

Pulmonary embolism

2.13 (1.39-3.25)

8

16

Colorectal cancer

0.63 (0.43-0.92)

16

10

Endometrial cancer

0.83 (0.47-1.47)

6

5

Hip fracture

0.66 (0.45-0.98)

15

10

Death due to causes other than the events above

0.92 (0.74-1.14)

40

37

Global index^c

1.15 (1.03-1.28)

151

170

Deep vein thrombosis^d

2.07 (1.49-2.87)

13

26

Vertebral fractures^d

0.66 (0.44-0.98)

15

9

Other osteoporotic fractures^d

0.77 (0.69-0.86)

170

131

^aadapted from JAMA, 2002; 288:321-333.

^bincludes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.

^ca subset of the events was combined in a "global index", defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.

^dnot included in Global Index.

*nominal confidence intervals unadjusted for multiple looks and multiple comparisons.

For those outcomes included in the "global index," absolute excess risks per 10,000 women-years in the group treated with CE/MPA were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the "global index" was 19 per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. (See BOXED WARNINGS, WARNINGS, and PRECAUTIONS.)

Bookmark this page: